patent.fyi
Applications  /  US 2026/0355516
United States Patent Application Publication

US 2026/0355516 A1

Published
Nov 12, 2026
Filed
May 7, 2026
Earliest date on the face
Feb 12, 2018
Classification
A61N 1/36053
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Persistent hypotension as trigger

What ifWhat if a resuscitation pathway opened when arterial pressure stayed low after an initial fluid challenge?
Claim language“identifying a subject as having sepsis”

An arterial catheter and pressure transducer provide a continuous mean arterial pressure reading. Persistent pressure below 65 mm Hg after initial fluid resuscitation triggers titration of a vasopressor infusion to support perfusion while the cause of hypotension is investigated.

1.1Drainable abscess as trigger

What ifWhat if a localized fluid collection on imaging triggered intervention?
Claim language“identifying a subject as having sepsis”

Computed tomography shows the position of an abdominal collection and its relation to bowel and blood vessels. A clinician places a drainage catheter through a suitable access path, removes infected fluid, and sends a sample for culture.

1.2Intravenous antimicrobial therapy

What ifWhat if intravenous antimicrobials addressed the infection driving sepsis?
Claim language“selectively electrically stimulating cholinergic neuronal activity”

An infusion pump delivers antimicrobials selected for the suspected infection source and likely organisms. Culture and susceptibility results guide subsequent drug selection, and kidney function guides dose adjustment where applicable.

1.2Removal of infected hardware

What ifWhat if removal of an infected vascular catheter provided source control?
Claim language“selectively electrically stimulating cholinergic neuronal activity”

A clinician removes the implicated catheter and establishes separate vascular access when ongoing infusion is required. Removal takes out the biofilm-bearing surface, and systemic antimicrobials address organisms circulating in the blood.

1.2Mixed fiber vagal stimulation

What ifWhat if a single cuff pulse train recruited both sensory and motor vagal fibers?
Claim language“no other vagal nerve activity is selectively electrically stimulated”

A two-contact cuff applies charge-balanced pulses across the cervical vagus in an experimental inflammation model. Recording cuffs on either side measure propagation, and serum tumor necrosis factor measurements track the inflammatory response.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Selective vagal stimulation in veterinary intensive care

A veterinary intensive care workstation records the clinician’s identification of sepsis or developing sepsis in the animal. A bipolar cuff on a mapped vagal branch connects to an isolated, charge-balanced pulse generator, and a second cuff records evoked responses. During setup, the operator uses a recruitment map with independently characterized target and off-target responses to select a contact pair and current window. The generator delivers stimulation within that window and suspends output when monitoring detects an off-target response.

Component substitution

Segmented silicone cuff for directional stimulation

A segmented silicone cuff with platinum-iridium contacts replaces the fixed bipolar electrode in the stimulator used after sepsis identification. A switch matrix connects individual circumferential contacts to the current source and return to change the electric field around the nerve. Calibration sweeps the contact configurations and compares their evoked responses with a separately established recruitment map. The controller stores the configurations that recruit the mapped cholinergic target below the measured thresholds of monitored off-target pathways.

Parameter or scale variation

Programmable burst timing with matched pulse counts

After sepsis identification, a pulse generator drives the selected cuff contacts within the mapped current window and delivers two timing programs with 30 pulses per 60-second cycle. One program distributes three 10-pulse bursts at 10 Hz, starting at 0, 20, and 40 seconds, and the other delivers one 30-pulse burst at 10 Hz. Both programs use the same charge-balanced pulse waveform and current amplitude. The controller timestamps stimulation and serum sampling so that changes in tumor necrosis factor can be compared at matched intervals.

Combination with existing systems

Bedside monitor interlock for vagal stimulation

An isolated interface connects the vagal pulse generator to a bedside monitor that streams heart rate and arterial pressure. After a clinician identifies sepsis or developing sepsis and enables stimulation, the generator uses the mapped contact configuration and current window. The interface pauses output when either vital sign crosses a clinician-set limit or the monitor stream becomes stale. The event recorder stores monitor readings and pulse timestamps on a common time base.

Automated or data-driven variant

Automated selection of vagal stimulation contacts

A controller connects a multichannel stimulating cuff and a downstream recording cuff to an isolated current source and a multichannel amplifier. After sepsis identification, it records time-aligned neural responses during a current sweep for each contact pair and compares them with subject-specific response templates established during pathway characterization. The controller selects the pair with the widest measured current interval between target recruitment and the first monitored off-target response. A periodic response check suspends output when the target response falls outside its calibrated range or an off-target response appears.

Serum cytokine feedback for burst scheduling

After a clinician identifies sepsis or developing sepsis, an automated immunoassay analyzer sends timestamped serum tumor necrosis factor measurements to the stimulation controller through a laboratory results interface. The controller holds contact selection, pulse width, and current within the mapped recruitment window and changes only the interval between bursts. A rate-limited rule compares consecutive accepted results with a clinician-set concentration band and adjusts the interval within programmed bounds. Missing or flagged results suspend automatic adjustment and trigger a request for review.

Specific version of a part

Infection and organ dysfunction assessment

A clinician identifies suspected infection from examination, imaging, and microbiology findings. A rise of at least two points from baseline on a composite organ dysfunction score supports identification of sepsis when the change is attributable to infection.

Serial assessment of kidney function

For a subject with suspected infection, a urine collection system records hourly output and serial blood samples measure creatinine. A clinician compares both trends with baseline and evaluates whether acute kidney dysfunction is attributable to the infection.

Current steering with cuff contacts

A multicontact cuff delivers charge-balanced biphasic pulses through individually controlled contacts on the vagus. In a preclinical setup, recordings from independently identified cholinergic neurons and sampled other vagal populations guide selection of a contact pattern and current range that recruit the cholinergic neurons without detectable recruitment of the other monitored populations.

Targeted intrafascicular pulse delivery

A thin insulated electrode with an exposed tip delivers biphasic current pulses within a vagal fascicle in a preclinical preparation. Recordings from identified cholinergic fibers and sampled neighboring fibers establish whether the site has a current window for cholinergic recruitment alone.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2014/0120174 A1
Published
May 1, 2014
Filed
Oct 30, 2013
Class
G01N 33/6893
Document BUS 8,996,116 B2
Published
Mar 31, 2015
Filed
Nov 1, 2010
Class
A61N 1/36053
Document CUS 2008/0138832 A1
Published
Jun 12, 2008
Filed
Sep 25, 2007
Class
G01N 33/53
Claim 1
Document A
Document B
1.1a) identifying a subject as having sepsis or as developing sepsis; and
The present invention is directed to a method for identifying and treating a subject with sepsis or severe sepsis, the method comprising obtaining a biological sample comprising blood from the subject; determining the level of soluble CD25 (sCD25) and pancreatic stone protein (PSP) in the biological sample from the subject; comparing the levels of sCD25 and PSP in the biological sample to reference levels of sCD25 and PSP; identifying the subject as having sepsis or severe se
A · US 2014/0120174 A1 · ¶ 6
1.2b) treating the subject by selectively electrically stimulating cholinergic neuronal activity in a vagal nerve of the subject, wherein no other vagal nerve activity is selectively electrically stimulated, effective to treat sepsis or development of sepsis in the subject.
For example, in some variations, the step of electrically stimulating the neuronal cholinergic anti-inflammatory pathway comprises electrically stimulating the vagus nerve with between about 0.5 to about 2.0 mA of current.
B · US 8,996,116 B2 · ¶ 16

An empty cell means only that no passage was reproduced there.

Statements in these documents
Accordingly, there remains a great need for more accurate and precise markers for sepsis, severe sepsis or septic shock.
A · US 2014/0120174 A1 · ¶ 5
The biomarkers may be used to identify a patient with sepsis or severe sepsis/septic shock, identify a patient as a candidate for sepsis therapy, to classify a patient's risk of developing severe sepsis or septic shock, or to classify a patient's sepsis stage or risk of progression of sepsis, as well as to determine a diagnosis, prognosis, or a treatment regimen.
A · US 2014/0120174 A1 · ¶ 2
The invention(s) described herein generally relate to methods and devices (including systems) for the treatment of pain by the modulating another pain therapy with co-stimulation of the cholinergic anti-inflammatory pathway.
B · US 8,996,116 B2 · ¶ 4
Traditional pain drugs often to fail to quell neuropathic pain, particularly when the underlying source of the pain is due (at least in part) to the dysfunction of glial cells.
B · US 8,996,116 B2 · ¶ 6
Cite aspatent.fyi, US 2026/0355516 A1, claim 1, first published 2026-11-19T12:21:55-05:00, https://patent.fyi/US20260355516/, SHA-256 bfa099800c0b9e3215e59937b2669d5da12071cabdbd7488a8fc2f10859b2b7c
First published
Permanent addresshttps://patent.fyi/US20260355516/
Content fingerprint (SHA-256)bfa099800c0b9e3215e59937b2669d5da12071cabdbd7488a8fc2f10859b2b7c
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi